IR@PKUHSC  > 北京大学药学院
学科主题药学
The comparisons of the efficacy and toxicity between gefitinib and docetaxel for patients with advanced nonsmall-cell lung cancer: A meta-analysis from randomized controlled clinical trials
Zhao, Y. L.1; Han, S.2,3; Pu, R.4; Shi, L. W.1,3
关键词Docetaxel Gefitinib Meta-analysis Nsclc
刊名INDIAN JOURNAL OF CANCER
2014-03-01
DOI10.4103/0019-509X.154070
suppl.3期:7页:86-91
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology
研究领域[WOS]Oncology
关键词[WOS]PHASE-III TRIAL ; PLATINUM-BASED CHEMOTHERAPY ; PERFORMANCE STATUS ; MUTATIONS ; MORTALITY ; THERAPY ; QUALITY ; CHINA
英文摘要

Background: The extent of the benefit of gefitinib in the treatment of advanced nonsmall-cell lung cancer (NSCLC) is till controversial, when compared with docetaxel. We performed this meta-analysis to compare the efficacy and toxicity of gefitinib with docetaxel for different patients with advanced NSCLC. Materials and Methods: We searched PubMed, Cochrane Library, and identified 5 randomized controlled clinical trials published within 2000-2013. After further full-text screening, 4 clinical trials were included in the final meta-analysis. Results: The outcomes of treatment efficacy included progression-free survival (PFS), overall survival (OS) and objective response rate (ORR). Comparing gefitinib to docetaxel for advanced NSCLC patients, the pooled hazard ratio (HR) of PFS was 0.91, (95% confidential index [CI] = 0.83-0.99), the pooled HR of OS was 1.02, (95% CI = 0.93-1.13), the pooled risk ratio of ORR was 1.57, (95% CI = 1.01-2.47). Conclusions: Gefitinib was found to significantly improve patients PFS and response rate compared with docetaxel. There is no difference of OS between gefitinib and docetaxel.

语种英语
WOS记录号WOS:000352281900005
Citation statistics
Cited Times:1[WOS]   [WOS Record]     [Related Records in WOS]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/57373
Collection北京大学药学院
北京大学临床肿瘤学院_日间化疗病区
作者单位1.Peking Univ, Sch Publ Hlth, Beijing 100191, Peoples R China
2.China Natl Ctr Biotechnol Dev, Beijing 100039, Peoples R China
3.Peking Univ, Sch Pharmaceut Sci, Beijing 100191, Peoples R China
4.Peking Univ, Int Res Ctr Med Adm, Beijing 100191, Peoples R China
Recommended Citation
GB/T 7714
Zhao, Y. L.,Han, S.,Pu, R.,et al. The comparisons of the efficacy and toxicity between gefitinib and docetaxel for patients with advanced nonsmall-cell lung cancer: A meta-analysis from randomized controlled clinical trials[J]. INDIAN JOURNAL OF CANCER,2014,suppl.3(7):86-91.
APA Zhao, Y. L.,Han, S.,Pu, R.,&Shi, L. W..(2014).The comparisons of the efficacy and toxicity between gefitinib and docetaxel for patients with advanced nonsmall-cell lung cancer: A meta-analysis from randomized controlled clinical trials.INDIAN JOURNAL OF CANCER,suppl.3(7),86-91.
MLA Zhao, Y. L.,et al."The comparisons of the efficacy and toxicity between gefitinib and docetaxel for patients with advanced nonsmall-cell lung cancer: A meta-analysis from randomized controlled clinical trials".INDIAN JOURNAL OF CANCER suppl.3.7(2014):86-91.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
谷歌学术
谷歌学术Similar articles in
[Zhao, Y. L.]'s Articles
[Han, S.]'s Articles
[Pu, R.]'s Articles
百度学术
百度学术Similar articles in
[Zhao, Y. L.]'s Articles
[Han, S.]'s Articles
[Pu, R.]'s Articles
必应学术
必应学术Similar articles in
[Zhao, Y. L.]'s Articles
[Han, S.]'s Articles
[Pu, R.]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.